Quantum Blue TDM

Quantum Blue® TDM

The BUHLMANN Quantum Blue® Technology offers rapid and reliable applications for TDM. Quantum Blue® TDM assays are lateral flow immunoassays for the quantitative determination of trough levels of adalimumab and infliximab in serum samples.

Quantum Blue® Adalimumab, Anti-Adalimumab, Infliximab, and Anti-Infliximab are for Research Use Only in the US. Not for use in diagnostic procedures.
Quantum Blue® Adalimumab: Health Canada Licence: 101776
Quantum Blue® Infliximab: Health Canada License: 98838

Quantum Blue®Adalimumab

The Quantum Blue®Adalimumab assay measures from 1.3 to 35 µg/ml, and the target concentrations lies well within the linear range of the test. Quantum Blue® Adalimumab is unique in the diagnostics market, being the first test that can provide fast, reliable information for adalimumab and it correlates well with the standard routine ELISAs for adalimumab level determinations.

Quantum Blue®Anti-Adalimumab

The Quantum Blue® Anti-Adalimumab assay allows for a highly sensitive detection of antibodies against adalimumab within 15 min. This drug sensitive assay (measures non-antibody bound drug) combined with ease of use and a short incubation time offers a fast and reliable measurement of free anti-drug antibodies. Quantum Blue® Adalimumab together with Quantum Blue® Anti-Adalimumab offers the complete solution for rapid testing on the popular Quantum Blue® platform.

Quantum Blue® Infliximab

The Quantum Blue® Infliximab assay measures from 0.4 to 20 µg/ml, and the target concentrations lies well within the linear range of the test. Quantum Blue® Infliximab provides a quantitative result within 15 minutes of incubation time. Quantum Blue® Infliximab is unique, being the only test that can provide fast, reliable information for infliximab, and correlating well with the standard routine ELISAs for determination of infliximab levels.

Quantum Blue® Anti-Infliximab

The Quantum Blue® Anti-Infliximab assay allows for a highly sensitive detection of antibodies against adalimumab within 15 min.  This drug sensitive assay (measures non-antibody bound drug) combined with ease of use and a short incubation time offers a fast and reliable measurement of free anti-drug antibodies. Quantum Blue® Infliximab together with Quantum Blue® Anti-Infliximab offers the complete solution for rapid testing on the popular Quantum Blue® platform.